Breathe Right International Sales Key To CNS’ $180 Mil. Revenue Target
This article was originally published in The Tan Sheet
Executive Summary
CNS is aiming to more than double its revenue in the next five to seven years through extensions of its Breathe Right nasal strip brand in the U.S. and aggressive international expansion
You may also be interested in...
Breathe Right Children's Products Provide "Drug-Free" Cold Remedy
CNS' two new children's Breathe Right nasal strips, now reaching food, drug and mass outlets nationwide, offer a new solution for the "winter woes of a stuffy nose," according to the company.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands